Compare · BDX vs STIM
BDX vs STIM
Side-by-side comparison of Becton Dickinson and Company (BDX) and Neuronetics Inc. (STIM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and STIM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $40.54B, about 378.3x STIM ($107.2M).
- Over the past year, BDX is down 13.1% and STIM is down 59.4% - BDX leads by 46.3 points.
- STIM has been more active in the news (14 items in the past 4 weeks vs 9 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 4 for STIM).
- Company
- Becton Dickinson and Company
- Neuronetics Inc.
- Price
- $147.15-0.85%
- $1.54-0.32%
- Market cap
- $40.54B
- $107.2M
- 1M return
- +1.27%
- -8.85%
- 1Y return
- -13.13%
- -59.40%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 4
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
- Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by Becton Dickinson and Company
- SEC Form 4 filed by Director Huffines Robert Luther
Latest STIM
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)
- Director Cucuz Sasha was granted 30,000 shares, increasing direct ownership by 2% to 1,542,798 units (SEC Form 4)
- Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 14% to 251,716 units (SEC Form 4)
- Director Cascella Robert was granted 36,250 shares, increasing direct ownership by 6% to 625,017 units (SEC Form 4)
- Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 71% to 72,500 units (SEC Form 4)
- SEC Form 8-K filed by Neuronetics Inc.
- SEC Form 8-K filed by Neuronetics Inc.
- Amendment: Former EVP, CFO and Treasurer Pfanstiel Steven sold $11,482 worth of shares (8,569 units at $1.34), decreasing direct ownership by 1% to 836,643 units (SEC Form 4) to satisfy withholding tax